

Project:



Analysing Plasma Coagulation Time

Analysis of Nanoparticle Effects on Plasma Coagulation Time in vitro

AUTHORED BY:	DATE:
Neill Liptrott	02.02.2016
Matthias Rösslein	08.07.2019

REVIEWED BY:	DATE:
Matthias Rösslein	21.02.2016
Matthias Rösslein	30.03.2017

APPROVED BY:	DATE:
Matthias Rösslein	23.03.2016
Matthias Rösslein	30.03.2017
Matthias Rösslein	08.07.2019

DOCUMENT HISTORY

Effective Date	Date Revision Required	Supersedes
08.07.2019	-	30.03.2017

Version	Approval Date	Description of the Change	Author / Changed by
1.0	02.02.2016	All Initial Document	Neill Liptrott

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		1/14

Version	Approval Date	Description of the Change		Author / Changed by
1.3	30.03.2017	All	Additions and small corrections	Neill Liptrott
1.3.1	08.07.2019		Reference to original NCL-SOP added	Matthias Rösslein

This SOP is based on the NCL Method ITA-12 - Analysis of Nanoparticle Effects on Plasma Coagulation Times in Vitro, Marina A. Dobrovolskaia, Ph.D., Nanotechnology Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21702 USA – September 2015

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		2/14

Table of Content

1	Introduction	4
2	Principle of the Method.....	4
3	Applicability and Limitations (Scope)	4
4	Related Documents	4
5	Equipment and Reagents.....	5
5.1	Equipment	5
5.2	Reagents	5
5.3	Reagent Preparation	5
6	Procedure	6
6.1	Preparation of Study Samples.....	6
6.2	Preparation of Test, Normal and Abnormal Control plasma samples	7
6.2.1	Test-Plasma.....	7
6.2.2	Nanoparticle-treated test-plasma	7
6.2.3	Normal and Abnormal (Coag N+ABN) control plasmas.....	8
6.2.4	Reagents used to initiate plasma coagulation (Neoplastin, PTTa-reagent, Thrombin)	8
6.3	Flow chart overview of experimental procedure.....	9
6.4	Experimental procedure	9
7	Quality Control/Assurance.....	10
8	Acceptance Criteria	11
9	Health and Safety Warnings, Cautions and Waste Treatment	11
10	Abbreviations	11
11	References	12
12	Annex.....	13

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		3/14

1 Introduction

This document describes a protocol for assessing the effect a nanoparticle formulation may have on plasma coagulation time. Coagulation, i.e, blood clotting, is a highly complex process that involves many components. There are three main pathways for coagulation: intrinsic (also known as the contact activation pathway, because it is activated by a damaged surface); extrinsic (also known as the tissue factor pathway); and the final common pathway. Each pathway can be assessed by a specialized test. For example, the activated partial thromboplastin time (APTT) assay is used to assess the intrinsic pathway, while the prothrombin time (PT) assay is a measure of the extrinsic pathway. Extrinsic and intrinsic pathways converge into common pathway. Thrombin time (TT) is an indicator of the functionality of the final common pathway. Each pathway involves many coagulation factors, some of which overlap between pathways. The APTT assay assesses functionality of factors XII, XI, IX, VIII, X, V, II. The PT assay assesses activity of factors VII, X, V and II. All three assays assess the role of fibrinogen.

2 Principle of the Method

This assay describes the analysis of plasma coagulation via three separate tests: prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT). Nanoparticles are incubated with fresh human plasma and assayed for coagulation time, compared to standard controls for each assay, using a coagulometer. When normal plasma is exposed to nanomaterials *in vitro*, and it results in depletion or inhibition of a certain coagulation factor, a delay in plasma coagulation is expected.

3 Applicability and Limitations (Scope)

This assay is for the assessment of plasma coagulation, *in vitro*, in response to known activators of plasma coagulation. Additionally the impact of nanoparticles on plasma coagulation in response to known activators of coagulation is assessed. The purpose of this assay is not to determine the mechanism by which nanoparticles may alter plasma coagulation times. Further follow up experiments should be conducted by which the mechanism(s) may be confirmed.

4 Related Documents

Table 1:

Document ID	Document Title
-------------	----------------

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		4/14

5 Equipment and Reagents

5.1 Equipment

- 5.1.1 Centrifuge capable of operating at 2500 x g
- 5.1.2 Refrigerator, 2-8°C
- 5.1.3 Merlin MC4+ Coagulometer (Hart Biologicals, UK)
- 5.1.4 Metal balls and cuvettes for coagulometer (Hart Biologicals, HB-1123-FG)
- 5.1.5 Pipettes covering a range of 0.05 to 10mL
- 5.1.6 Finntip, 5mL (ThermoScientific, 9404180)

5.2 Reagents

- 5.2.1 Human blood from at least three donors, anti-coagulated with sodium citrate
- 5.2.2 Neoplastine CI (Diagnostica Stago, 00666)
- 5.2.3 Thrombin (Diagnostica Stago, 00611)
- 5.2.4 CaCl₂ (0.025M) (Diagnostica Stago, 00367)
- 5.2.5 Owren-Koller Buffer (Diagnostica Stago, 00360)
- 5.2.6 PTTA (Diagnostica Stago, 00595)
- 5.2.7 CoagControl N+ABN (Diagnostica Stago, 00676)
- 5.2.8 RPMI
- 5.2.9 PBS (GE Life Sciences, SH 30256.01)

5.3 Reagent Preparation

Reagents should be warmed to 37°C using the reagent and cuvette pre-heating station prior to addition to test plasma samples.

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		5/14

6 Procedure

6.1 Preparation of Study Samples

This assay requires 500 μL of nanoparticles, at a concentration 10x that of the highest tested concentration, dissolved/resuspended in PBS or other relevant media. The concentration is selected based on the plasma concentration of the nanoparticle at the intended therapeutic dose. For the purpose of this protocol this concentration is called “theoretical plasma concentration”.

Considerations for estimating theoretical plasma concentration were reviewed elsewhere (1) and are summarized in Box 1 below.

Box 1. Example Calculation of Nanoparticle concentration for In Vitro Test

In this example, we assume the mouse dose is known to be 123 mg/kg.

$$\text{human dose} = \frac{\text{mouse dose}}{12.3} = \frac{123 \frac{\text{mg}}{\text{kg}}}{12.3} = 10 \text{ mg/kg}$$

Blood volume constitutes approximately 8% of body weight, (e.g. a 70 kg human has approximately 5.6 L (8% of 70) of blood). This allows us to get a very rough estimation of what the maximum blood concentration may be.

$$\begin{aligned} \text{in vitro concentration}_{\text{human matrix}} &= \frac{\text{human dose}}{\text{human blood volume}} = \frac{70 \text{ kg} \times 10 \frac{\text{mg}}{\text{kg}}}{5.6 \text{ L}} \\ &= \frac{700 \text{ mg}}{5.6 \text{ L}} = 0.125 \text{ mg/mL} \end{aligned}$$

The assay will evaluate 4 concentrations: 10 X (or when feasible 100X, 30X or 5X) of the theoretical plasma concentration, theoretical plasma concentration and two 1:5 serial dilutions of the theoretical plasma concentration. When the intended therapeutic concentration is unknown, the highest final concentration is 1 mg/mL or the highest reasonably achievable concentration.

For example, if the final theoretical plasma concentration to be tested is 0.2 mg/mL, then a stock of 20 mg/mL will be prepared and diluted 10 fold (2 mg/mL), followed by two 1:5 serial dilutions (0.4 and 0.08 mg/mL). When 0.1 mL of each of these samples is added to the test tube and mixed with 0.9 mL of plasma, the final nanoparticle concentrations tested in the assay are: 2.0, 0.2, 0.04 and 0.008 mg/mL.

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		6/14

6.2 Preparation of Test, Normal and Abnormal Control plasma samples

6.2.1 Test-Plasma

- Use freshly collected whole blood within 1 h after collection.
- Spin the blood 10 min, 2500 x g at 20-22°C;
- collect plasma and pool from at least 2 donors.
- Pooled plasma is stable for 8 h at room temperature.
- Do not refrigerate or freeze.
- The assay can also be performed in the plasma from individual donors when needed for mechanistic follow up experiments.
- Analyze 2 duplicates (4 total samples) of test-plasma in each of the coagulation assays;
- run one duplicate before the nanoparticle samples and the second duplicate at the end of each run to verify that the plasma functionality is not affected throughout the duration of the experiment.

6.2.2 Nanoparticle-treated test-plasma

- In a microcentrifuge tube, combine 100 µL of nanoparticles (as prepared in step 4) and 900 µL of test plasma;
- mix well and incubate 30 minutes at 37°C.
- Prepare three tubes for each test sample (i.e. when each nanoparticle is tested at 4 concentrations,
- one needs 3 tubes for each concentration, total 12 tubes per test-nanoparticle).

Note: Insoluble nanoparticles, which can be separated from the bulk plasma by centrifugation may be removed by spinning the test tubes for 5 min at 18,000 x g. it is assumed that any proteins involved in the coagulation process and adsorbed onto the particle surface will be removed from the sample in this step and the consequences of such binding on the plasma coagulation pathways will be assessed. Often nanoparticles are soluble or modified with poly(ethylene glycol), and therefore cannot be easily separated from plasma at the end of the incubation step. In this case, the sample analysis proceeds to the next step without centrifugation.

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		7/14

6.2.3 Normal and Abnormal (Coag N+ABN) control plasmas

- Reconstitute lyophilized control plasmas with 2 mL of distilled water.
- Let the solutions stand at room temperature 30 min prior to use.
- Mix thoroughly before use.
- Keep unused portion refrigerated and use within 48 h after reconstitution.
- These plasma samples are used as instrument controls.

6.2.4 Reagents used to initiate plasma coagulation (Neoplastin, PTTa-reagent, Thrombin)

- These reagents are supplied as lyophilized powder.
- Reconstitute according to the manufacturer's instructions and use fresh or refrigerate and use within the time specified by the manufacturer.

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		8/14

6.3 Flow chart overview of experimental procedure




Figure 1: Brief outline of the workflow.

6.4 Experimental procedure

- 6.4.1 Set-up instrument test parameters for each of the four assays. Refer to the Appendix for a quick list of instrument settings and reagent volumes. Allow the instrument to warm up 5-10 min prior to use.
- 6.4.2 Prepare all reagents and warm to 37°C prior to use. Note that lyophilized reagents should be reconstituted at least 30 minutes prior to use.
- 6.4.3 Place cuvettes into A, B, C and D test rows on the coagulometer *(Note: this protocol is based on the semi-automatic STArt4 coagulometer from Diagnostica Stago (2)). If*

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		9/14

using a different instrument, please follow the operational guidelines recommended by the instrument manufacturer).

- 6.4.4 Add one metal ball into each cuvette and allow cuvette and ball to warm for at least 3 minutes prior to use.
- 6.4.5 Add 100 µL of control or test plasma to a cuvette when testing PT or thrombin time, and 50 µL when testing APTT (refer to the Appendix for reference). Prepare 2 wells for each test-tube prepared in step 5.2
- 6.4.6 This step is only for APTT:

Add 50 µL of PTTa reagent to plasma samples in cuvettes.
- 6.4.7 Start the timer for each of the test rows by pressing the A, B, C or D timer buttons. Ten seconds before time is up, the timer starts beeping. When this happens, immediately transfer cuvettes to PIP row and press PIP button to activate pipettor.
- 6.4.8 When time is up, add coagulation activation reagent to each cuvette and record coagulation time. Refer to the Appendix for the type of coagulation activation reagent and volume for each of the four assays.

7 Quality Control/Assurance

- 7.1 A Percent Coefficient of Variation should be calculated for each control or test according to the following formula: $\%CV = SD/Mean \times 100\%$
- 7.2. Normal and Abnormal control plasma should coagulate within the time established by the certifying laboratory (e.g. for the most batches of control plasmas normal coagulation time in the PT assay is ≤ 12.6 seconds, APTT – ≤ 36.75 second and Thrombin – ≤ 16.9 seconds; abnormal control plasma coagulation time should be above these limits). When normal and abnormal control perform as described above and untreated plasma sample coagulates within normal time limits, both the instrument and the test plasma are qualified for the use in this test

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		10/14

- 7.3. Nanoparticles have no effect on the assay coagulation cascade when coagulation time of the test plasma samples after exposure to nanoparticles is within the normal limits.
- 7.4. Prolongation of the plasma coagulation time in plasma samples exposed to nanoparticles suggests that test-particle either deplete or inhibit coagulation factors. There is no guidance on the degree of prolongation, but in general prolongation of 2-fold or more than that in untreated control is considered physiologically significant

8 Acceptance Criteria

8. Acceptance Criteria

- 8.1 %CV for each control and test sample should be within 5%.
- 8.2 If two duplicates of the same study sample demonstrated results > 5% different, this sample should be reanalyzed.

9 Health and Safety Warnings, Cautions and Waste Treatment

Universal precautions must be used when handling human peripheral blood. No sharps are to be used in the preparation of cell isolates of plasma from human healthy volunteer blood. All liquid waste must be discarded into 1% Virkon solution and left overnight (18 hours) in a class II BSC with the lid loose to allow for venting.

10 Abbreviations

ABN	abnormal
API	active pharmaceutical ingredient
APPT	activated partial thromboplastin time
BSC	Biological Safety Cabinet
CV	coefficient of variation
P	pathologic
N	normal
PT	prothrombin time
SD	standard deviation
TT	thrombin time

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		11/14

11 References

1. Dobrovolskaia MA, McNeil SE. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release. 2013 Dec 10;172(2):456-66

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		12/14

12 Annex

Assay	Control	Instrument Settings				Volumes		Normal Coagulation Time
		Max Time	Incubation Time	Single/ Duplicate	Precision	Plasma and Reagent Volumes	Coagulation Activation Reagent Volumes	
PT (neoplastine)	Coag Control N+ABN	60 sec	120 sec	Duplicate	5%	100 µL Plasma	Neoplastine Reagent: 100 µL	≤ 12.6 sec
APTT	Coag Control N+ABN	120 sec	180 sec	Duplicate	5%	50 µL Plasma + 50 µL PTTA Reagent	CaCl ₂ : 50 µL	≤ 36.75 sec
Thrombine	Coag Control N+ABN	60 sec	60 sec	Duplicate	5%	100 µL Plasma	Thrombine: 100 µL	≤ 16.9 sec

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		13/14

Document Type	Document ID	Version	Status	Page
SOP	EUNCL-ITA12	1.3.1		14/14